retatrutide cagrilintide blend vs Cagrilintide: The Ultimate Weight Loss Peptide Comparison Reta/Cagri Blend – 12.5mg/2.5mg |

E66.01 (Morbid (severe) obesity due to excess calories) is the strongest diagnosis code for weight management claims

GLP-1 use is safe and effective with many pre-existing conditions with the exception of the following: Currently pregnant Currently breastfeeding Currently being treated for cancer Active eating disorder Active gallbladder disease Active substance abuse or dependency Type 1 diabetes Bariatric surgery (within the past 18 months) Pancreatitis within the past 6 months, or a history of pancreatiitis caused by taking a GLP-1 Personal or family history of medullary thyroid cancer or MEN syndrome Personal history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

FDA approval status Most peptides discussed by Rogan and the biohacking community lack FDA approval for the conditions people use them for

Additionally, there is a controlling role of the pentadecapeptide BPC 157 against the tumor-promoting effects of many growth factors and peptides (Sikiric et al., 2018) as well as counteracting harmful escape from the initial healing effect (i.e., angiogenesis)